JP2020517295A5 - - Google Patents

Download PDF

Info

Publication number
JP2020517295A5
JP2020517295A5 JP2019558623A JP2019558623A JP2020517295A5 JP 2020517295 A5 JP2020517295 A5 JP 2020517295A5 JP 2019558623 A JP2019558623 A JP 2019558623A JP 2019558623 A JP2019558623 A JP 2019558623A JP 2020517295 A5 JP2020517295 A5 JP 2020517295A5
Authority
JP
Japan
Prior art keywords
module
receptor
ligand
target
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019558623A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517295A (ja
JP7538601B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/029218 external-priority patent/WO2018200583A1/en
Publication of JP2020517295A publication Critical patent/JP2020517295A/ja
Publication of JP2020517295A5 publication Critical patent/JP2020517295A5/ja
Priority to JP2023216495A priority Critical patent/JP2024038039A/ja
Application granted granted Critical
Publication of JP7538601B2 publication Critical patent/JP7538601B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019558623A 2017-04-26 2018-04-24 キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用 Active JP7538601B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023216495A JP2024038039A (ja) 2017-04-26 2023-12-22 キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762490578P 2017-04-26 2017-04-26
US201762490576P 2017-04-26 2017-04-26
US201762490580P 2017-04-26 2017-04-26
US62/490,578 2017-04-26
US62/490,580 2017-04-26
US62/490,576 2017-04-26
PCT/US2018/029218 WO2018200583A1 (en) 2017-04-26 2018-04-24 Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023216495A Division JP2024038039A (ja) 2017-04-26 2023-12-22 キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用

Publications (3)

Publication Number Publication Date
JP2020517295A JP2020517295A (ja) 2020-06-18
JP2020517295A5 true JP2020517295A5 (https=) 2021-06-10
JP7538601B2 JP7538601B2 (ja) 2024-08-22

Family

ID=63918704

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019558623A Active JP7538601B2 (ja) 2017-04-26 2018-04-24 キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用
JP2019558421A Pending JP2020517287A (ja) 2017-04-26 2018-04-24 キメラ抗体/t細胞受容体構築物及びその使用
JP2023051860A Pending JP2023093472A (ja) 2017-04-26 2023-03-28 キメラ抗体/t細胞受容体構築物及びその使用
JP2023216495A Withdrawn JP2024038039A (ja) 2017-04-26 2023-12-22 キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019558421A Pending JP2020517287A (ja) 2017-04-26 2018-04-24 キメラ抗体/t細胞受容体構築物及びその使用
JP2023051860A Pending JP2023093472A (ja) 2017-04-26 2023-03-28 キメラ抗体/t細胞受容体構築物及びその使用
JP2023216495A Withdrawn JP2024038039A (ja) 2017-04-26 2023-12-22 キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用

Country Status (13)

Country Link
US (5) US11965021B2 (https=)
EP (2) EP3615046A4 (https=)
JP (4) JP7538601B2 (https=)
KR (3) KR102762834B1 (https=)
CN (2) CN110662547A (https=)
AU (3) AU2018258045B2 (https=)
CA (2) CA3059755A1 (https=)
IL (4) IL310182A (https=)
MX (1) MX2024007576A (https=)
PH (1) PH12019502411A1 (https=)
SG (5) SG10201913579WA (https=)
TW (4) TWI882944B (https=)
WO (3) WO2018200585A1 (https=)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
WO2018200585A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Cells expressing chimeric antigen receptors and secondary effectors and uses thereof
CN112888709B (zh) * 2018-03-30 2024-10-29 优瑞科生物技术公司 标靶cd22的构建体和其用途
SG11202012342WA (en) 2018-06-18 2021-01-28 Eureka Therapeutics Inc Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
BR112021001338A2 (pt) * 2018-07-26 2021-05-04 TCR2 Therapeutics Inc. composições e métodos para reprogramação de tcr usando proteínas de fusão específicas para o alvo
EP3670530A1 (en) * 2018-12-18 2020-06-24 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
CN111100199B (zh) * 2018-12-29 2021-02-12 北京百普赛斯生物科技股份有限公司 一种荧光素标记的蛋白四聚体及其制备方法与应用
CA3126422A1 (en) * 2019-01-14 2020-07-23 Nanjing Legend Biotech Co., Ltd. Chimeric receptor polypeptides and uses thereof
US20220162312A1 (en) * 2019-01-28 2022-05-26 WuXi Biologics Ireland Limited Novel bispecific cd3/cd20 polypeptide complexes
US20220127372A1 (en) * 2019-02-01 2022-04-28 Cafa Therapeutics Limited Tcr fusion protein and cell expressing tcr fusion protein
KR20220040483A (ko) 2019-07-26 2022-03-30 얀센 바이오테크 인코포레이티드 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는 단백질 및 이의 용도
CA3174575A1 (en) * 2020-03-02 2021-09-10 The Regents Of The University Of California Chimeric antigen receptors and related methods and compositions for the treatment of cancer
JP2023518049A (ja) * 2020-03-16 2023-04-27 ユニバーシティ オブ サザン カリフォルニア 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体
IL296511A (en) 2020-03-20 2022-11-01 Lyell Immunopharma Inc Novel recombinant cell surface markers
EP4127188A4 (en) 2020-03-31 2024-08-21 Walking Fish Therapeutics MODIFIED B CELLS AND METHODS OF USE THEREOF
CA3173480A1 (en) * 2020-03-31 2021-10-07 Kathleen Boyle Modified b cells and methods of use thereof
CN112830973B (zh) * 2020-04-08 2022-11-01 苏州克睿基因生物科技有限公司 嵌合多肽及其用途
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
KR102931002B1 (ko) * 2020-05-07 2026-02-24 브리스타 이뮤노테크 리미티드 개선된 t 세포 수용체-공동자극 분자 키메라
KR20230058013A (ko) * 2020-05-25 2023-05-02 브리스타 이뮤노테크 리미티드 향상된 합성 t 세포 수용체 및 항원 수용체
AU2021308702A1 (en) 2020-07-17 2023-03-16 Instil Bio (Uk) Limited Receptors providing targeted costimulation for adoptive cell therapy
CN116761815A (zh) * 2020-07-29 2023-09-15 优瑞科生物技术公司 T细胞和嵌合刺激受体及其应用
WO2022164959A1 (en) 2021-01-27 2022-08-04 Lyell Immunopharma, Inc. Improved immune cell therapy
KR20230150833A (ko) 2021-02-25 2023-10-31 라이엘 이뮤노파마, 인크. 세포 배양 방법
EP4298230A1 (en) 2021-02-25 2024-01-03 Lyell Immunopharma, Inc. Codon-optimized nucleotide sequences encoding an ap-1 transcription factor
CN114957481A (zh) * 2021-02-25 2022-08-30 华夏英泰(北京)生物技术有限公司 针对cd19和cd22的双靶点star
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
KR20240027676A (ko) 2021-06-02 2024-03-04 라이엘 이뮤노파마, 인크. Nr4a3-결핍 면역 세포 및 이의 용도
EP4355340A4 (en) 2021-06-16 2025-05-21 Instil Bio, Inc. RECEPTORS FOR TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY
EP4370213A4 (en) 2021-07-16 2025-06-04 Instil Bio (Uk) Limited Chimeric molecules for targeted costimulation for adoptive cell therapy
KR20240038974A (ko) * 2021-07-29 2024-03-26 난트셀, 인크. 바이러스 감염 및 암의 예방 및 치료를 위한 변형된 t 세포 수용체
WO2023070041A1 (en) 2021-10-21 2023-04-27 Lyell Immunopharma, Inc. Enhanced immune cell therapy
KR20240112376A (ko) 2021-10-28 2024-07-18 라이엘 이뮤노파마, 인크. c-Jun을 발현하는 세포를 배양하는 방법
US20230181644A1 (en) 2021-10-28 2023-06-15 Lyell Immunopharma, Inc. Methods of generating cells
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ror1結合タンパク質を発現する細胞を培養する方法
WO2023133540A1 (en) 2022-01-07 2023-07-13 Lyell Immunopharma, Inc. Il-12 affinity variants
CN114591443A (zh) * 2022-03-07 2022-06-07 皖南医学院第一附属医院(皖南医学院弋矶山医院) 一种基于scTv的嵌合受体CSR及其应用
US20250281538A1 (en) 2022-05-02 2025-09-11 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Compositions targeting gpc2 and gpc3 and their use for treating solid tumors
KR20250027283A (ko) 2022-05-19 2025-02-25 라이엘 이뮤노파마, 인크. nr4a3을 표적하는 폴리뉴클레오타이드 및 이의 용도
CN119790063A (zh) 2022-07-22 2025-04-08 莱尔免疫制药股份有限公司 免疫细胞疗法
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2024148369A1 (en) 2023-01-07 2024-07-11 Lyell Immunopharma, Inc. Targeted il-12 affinity variants
WO2024182539A1 (en) 2023-02-28 2024-09-06 Lyell Immunopharma, Inc. Methods of culturing reprogrammed cells
AU2024309243A1 (en) 2023-06-27 2026-01-29 Lyell Immunopharma, Inc. Il-12 stability variants
CN121909034A (zh) 2023-07-24 2026-04-21 斯特兰德生物科技公司 用于产生用于体外细胞疗法的工程化免疫细胞的基于rna的合成回路
EP4520346A1 (en) 2023-09-06 2025-03-12 Gyncentrum Sp. z o.o. Cells, methods and systems for use in the treatment of a cancer with dual-car-t
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium
WO2026006604A1 (en) 2024-06-26 2026-01-02 Lyell Immunopharma, Inc. Feeder cell replacement

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3753357A (en) 1970-12-14 1973-08-21 Ovitron Res Corp Method and apparatus for the preservation of cells and tissues
US4199022A (en) 1978-12-08 1980-04-22 The United States Of America As Represented By The Department Of Energy Method of freezing living cells and tissues with improved subsequent survival
US4559298A (en) 1982-11-23 1985-12-17 American National Red Cross Cryopreservation of biological materials in a non-frozen or vitreous state
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL86278A (en) * 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
GB9221657D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
US5585358A (en) 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
JPH11510375A (ja) 1995-06-30 1999-09-14 コベンハブンズ ユニバーサイテッド ペプチド−mhc複合体を指向するファージディスプレイライブラリーからの組換え抗体
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
CA2510003A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
SI1629011T1 (sl) 2003-05-31 2010-05-31 Micromet Ag Humane molekule za vezavo anti hu cd
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
AU2005247950B2 (en) 2004-05-27 2012-02-02 Receptor Logic, Inc. Antibodies as T cell receptor mimics, methods of production and uses thereof
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN101316610A (zh) 2005-09-22 2008-12-03 艾润·R·科恩 T细胞受体恒定区的免疫原性片段及其衍生的肽
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
ES2547248T3 (es) 2006-04-28 2015-10-02 Delenex Therapeutics Ag Anticuerpos que se unen al dominio extracelular del receptor Tirosina cinasa ALK
CA2651174A1 (en) 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
JP2009536527A (ja) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
WO2007143104A2 (en) 2006-06-01 2007-12-13 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-cd19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
AU2008247819B2 (en) 2007-05-01 2013-02-14 Research Development Foundation Immunoglobulin Fc libraries
EP2144628B1 (en) 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
MX351227B (es) 2008-06-25 2017-09-14 Athenix Corp Genes de toxinas y métodos para su uso.
TWI580431B (zh) 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Hig2與urlc10抗原決定位胜肽以及含此胜肽之疫苗
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
WO2010059543A1 (en) 2008-11-20 2010-05-27 Merck Sharp & Dohme Corp. Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
US20100153133A1 (en) 2008-12-16 2010-06-17 International Business Machines Corporation Generating Never-Event Cohorts from Patient Care Data
WO2010091637A1 (en) 2009-02-10 2010-08-19 Shenogen Pharma Group Ltd. Antibodies and methods for treating estrogen receptor-associated diseases
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
AU2010277561A1 (en) 2009-07-30 2012-02-09 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Compositions for generating an antigen specific immune response
AU2010309438A1 (en) 2009-10-22 2012-06-07 Ricardo J. Moro Peptides that bind the alpha-fetoprotein (AFP) receptor and uses thereof
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
PT2552959T (pt) 2010-03-26 2017-04-21 Memorial Sloan Kettering Cancer Center Anticorpos para muc16 e métodos de utilização dos mesmos
WO2012050374A2 (en) 2010-10-13 2012-04-19 Innocell, Inc. Immunotherapy for solid tumors
US10239952B2 (en) 2011-04-01 2019-03-26 Memorial Sloan Kettering Cancer Center Anti-WT1/HLA bi-specific antibody
KR20140033029A (ko) 2011-04-01 2014-03-17 메모리얼 슬로안-케터링 캔서 센터 에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체
US20130280220A1 (en) * 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
EP2843051B1 (en) 2012-04-23 2018-06-06 GeneFrontier Corporation Anti-human cd69 antibody, and use thereof for medical purposes
CN103319595B (zh) 2012-07-04 2016-12-28 中国药科大学 抗人afp单链抗体以及融合抗原肽的制备方法和应用
KR20150029714A (ko) 2012-07-13 2015-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 이중특이적 항체의 공-도입에 의한 car 세포의 활성 증강
WO2014014796A1 (en) 2012-07-18 2014-01-23 Eli Lilly And Company Multi-specific igg-(fab)2 constructs containing t-cell receptor constant domains
CN104769103B (zh) 2012-09-04 2018-06-08 塞勒克提斯公司 多链嵌合抗原受体和其用途
AU2013327136A1 (en) 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
CN102993305B (zh) 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 人源抗人表皮生长因子受体抗体及其编码基因与应用
CA2894885A1 (en) 2012-12-13 2014-06-19 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
CN103965362B (zh) 2013-02-06 2019-02-01 上海细胞治疗集团有限公司 一种可使t细胞趋向肿瘤部位的嵌合趋化因子受体
CN104968491A (zh) 2013-02-06 2015-10-07 旭硝子株式会社 透明面材以及使用该透明面材的显示装置
PT2961831T (pt) 2013-02-26 2020-10-12 Memorial Sloan Kettering Cancer Center Composições e métodos para imunoterapêutica
EP2970371B1 (en) 2013-03-14 2019-07-31 Agrivida, Inc. Use of dimerization domains for temperature regulation of enzyme activity
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
JP6346266B2 (ja) 2013-03-21 2018-06-20 サンガモ セラピューティクス, インコーポレイテッド 操作されたジンクフィンガータンパク質ヌクレアーゼを使用するt細胞受容体遺伝子の標的化された破壊
KR101536668B1 (ko) 2013-06-18 2015-07-15 사회복지법인 삼성생명공익재단 인간 및 마우스 c-Met에 교차결합하는 항체 및 그의 용도
GB201313377D0 (en) 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
WO2015017214A1 (en) * 2013-07-29 2015-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
WO2015063069A1 (en) 2013-10-28 2015-05-07 Benjamin Felder Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
EP3066131A1 (en) 2013-11-07 2016-09-14 Memorial Sloan-Kettering Cancer Center Fc-enhanced anti-wt1/hla antibody
JP6553069B2 (ja) 2013-11-07 2019-07-31 メモリアル スローン ケタリング キャンサー センター 抗wt1/hla二重特異性抗体
SG10201913396RA (en) * 2014-02-28 2020-03-30 Ichnos Sciences SA Expression constructs and methods for selecting host cells expressing polypeptides
CN104087592B (zh) 2014-05-13 2016-01-27 天津医科大学总医院 Afp158-166特异性tcr基因及其转基因t细胞及体外增殖方法及用途
SI3194434T1 (sl) 2014-09-15 2019-11-29 Molmed Spa Himerni antigenski receptorji
EP3215164A1 (en) * 2014-11-03 2017-09-13 Immures S.r.l. T cell receptors
SI3227339T1 (sl) 2014-12-05 2022-02-28 Memorial Sloan-Kettering Cancer Center Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba
KR20240135036A (ko) 2014-12-05 2024-09-10 메모리얼 슬로안 케터링 캔서 센터 B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법
AU2015357526B2 (en) 2014-12-05 2022-03-17 Eureka Therapeutics, Inc. Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
EP3227324A4 (en) 2014-12-05 2018-08-29 Memorial Sloan Kettering Cancer Center Antibodies targeting g-protein coupled receptor and methods of use
WO2016090337A1 (en) 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
US11673957B2 (en) 2015-03-10 2023-06-13 Eureka Therapeutics, Inc. Anti-ROR2 antibodies
CN107667120B (zh) 2015-03-17 2022-03-08 纪念斯隆-凯特林癌症中心 抗muc16抗体及其应用
US10738116B2 (en) * 2015-03-19 2020-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
WO2016154047A2 (en) 2015-03-20 2016-09-29 Memorial Sloan-Kettering Cancer Center Monoclonal antigen-binding proteins to intracellular oncogene products
AU2016243026B2 (en) 2015-04-03 2022-03-31 Eureka Therapeutics, Inc. Constructs targeting AFP peptide/MHC complexes and uses thereof
CN107847570A (zh) 2015-05-08 2018-03-27 优瑞科生物技术公司 靶向hpv16‑e7肽/mhc复合体的构建体及其用途
EP3842072A1 (en) 2015-05-18 2021-06-30 Eureka Therapeutics, Inc. Anti-ror1 antibodies
CN108137669B (zh) 2015-05-18 2023-02-17 优瑞科生物技术公司 抗ror1嵌合抗原受体
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
TW201702272A (zh) 2015-05-22 2017-01-16 美國紀念斯隆 凱特琳癌症中心 Prame肽專一性類t細胞受體抗體
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
KR20180023949A (ko) 2015-06-09 2018-03-07 메모리얼 슬로안-케터링 캔서 센터 인간 hla에 의해 제시된 ebv 잠복성 막 단백질 2a 펩티드에 특이적인 t 세포 수용체-유사 항체 작용제
WO2016199414A1 (en) 2015-06-12 2016-12-15 Minebea Co., Ltd. Load detector and load detection system
HK1254803A1 (zh) 2015-06-23 2019-07-26 Memorial Sloan Kettering Cancer Center 新型pd -1的免疫调节剂
CN107922471A (zh) 2015-06-24 2018-04-17 优瑞科生物技术公司 靶向ny‑eso‑1肽/mhc复合物的构建体及其用途
WO2017004252A1 (en) 2015-06-30 2017-01-05 The Arizona Board Of Regents On Behalf Of The University Of Arizona Redirected cells with mhc chimeric receptors and methods of use in immunotherapy
US20200087400A1 (en) 2015-07-22 2020-03-19 Eureka Therapeutics, Inc. Constructs targeting psa peptide/mhc complexes and uses thereof
EP3331913A1 (en) * 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2017044699A1 (en) 2015-09-10 2017-03-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 chimeric antigen receptors
US20180258149A1 (en) 2015-09-17 2018-09-13 Novartis Ag Car t cell therapies with enhanced efficacy
IL299203A (en) 2015-10-13 2023-02-01 Eureka Therapeutics Inc ׂ A Delaware Corp Antibody factors specific for human differentiation group 19 and their uses
EP3842450A1 (en) 2015-10-23 2021-06-30 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
CN105331585A (zh) 2015-11-13 2016-02-17 科济生物医药(上海)有限公司 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
KR20180089497A (ko) 2015-12-04 2018-08-08 메모리얼 슬로안-케터링 캔서 센터 Fc 수용체-유사 5를 표적화하는 항체 및 사용 방법
JP7068169B2 (ja) * 2016-01-08 2022-05-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 条件付活性ヘテロ二量体ポリペプチド及びその使用方法
US11505599B2 (en) 2016-01-14 2022-11-22 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for Foxp3-derived peptides
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018057967A2 (en) 2016-09-23 2018-03-29 Eureka Therapeutics, Inc. Constructs targeting hiv peptide/mhc complexes and uses thereof
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
JP2020513754A (ja) 2016-12-21 2020-05-21 ティーシーアール2 セラピューティクス インク. がん治療用に操作されたt細胞
US20190359678A1 (en) 2017-02-09 2019-11-28 The Regents Of The University Of California Chimeric t cell antigen receptors and methods of use thereof
IL270138B2 (en) 2017-04-26 2025-08-01 Eureka Therapeutics Inc Structures that specifically recognize glypican 3 and their uses
WO2018200585A1 (en) * 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Cells expressing chimeric antigen receptors and secondary effectors and uses thereof
EP3638295A1 (en) 2017-06-13 2020-04-22 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN112888709B (zh) 2018-03-30 2024-10-29 优瑞科生物技术公司 标靶cd22的构建体和其用途
SG11202012342WA (en) 2018-06-18 2021-01-28 Eureka Therapeutics Inc Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
MX2021005751A (es) 2018-11-16 2021-10-01 Memorial Sloan Kettering Cancer Center Anticuerpos contra mucina 16 y métodos de uso de los mismos.
WO2020227538A1 (en) 2019-05-08 2020-11-12 Memorial Sloan Kettering Cancer Center Humanized antibodies to mucin-16 and methods of use thereof
WO2021016609A1 (en) 2019-07-24 2021-01-28 Eureka Therapeutics, Inc. Cells expressing chimeric antigen receptors and chimeric stimulating receptors and uses thereof
CN116761815A (zh) 2020-07-29 2023-09-15 优瑞科生物技术公司 T细胞和嵌合刺激受体及其应用

Similar Documents

Publication Publication Date Title
JP2020517295A5 (https=)
HRP20231542T1 (hr) Kimerni antigenski receptori koji ciljaju bcma i postupci njihove uporabe
JP2021094037A5 (https=)
JP2021087455A5 (https=)
JP2025028239A5 (https=)
FI4324851T3 (fi) BCMA-spesifisiä kimeerisiä antigeenireseptoreita ja niiden käyttöjä
JP2020533958A5 (https=)
JP2021500881A5 (https=)
HRP20241057T1 (hr) Kimerni antigenski receptori na osnovu jedno-domenskih antitijela i načini njihove uporabe
JP2019527557A5 (https=)
JP2022501043A5 (https=)
RU2020120853A (ru) Мультиспецифичные химерные рецепторы, содержащие домен nkg2d, и способы их применения
JP2017524367A5 (https=)
JP2020114264A5 (https=)
JP2018525033A5 (https=)
RU2018109426A (ru) Химерные антигенные рецепторы со встроенными контролируемыми функциями
HRP20211978T1 (hr) Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe
JP2018535701A5 (https=)
JP2018504094A5 (https=)
WO2012079000A4 (en) Use of chimeric antigen receptor-modified t cells to treat cancer
JP2018527014A5 (https=)
JP2021532742A5 (https=)
JP2021513857A5 (https=)
CN115916833A (zh) 靶向b7h3的抗原结合多肽及其应用
JPWO2020061498A5 (https=)